In this study, we tested whether tau deposition (measured with tau-positron emission tomography [PET]) was associated with GM network alterations (measured with structural magnetic resonance imaging [MRI]) in individuals across the AD spectrum and whether these relationships were differentially linked with disease severity. Here, MAPT is linked to Alzheimer disease.